Cyclin-dependent kinase inhibitor dinaciclib potently synergizes with cisplatin in preclinical models of ovarian cancer-Reference-Cited by-同舟云学术

Cyclin-dependent kinase inhibitor dinaciclib potently synergizes with cisplatin in preclinical models of ovarian cancer

Published:2015-03-30 Issue:17 Volume:6 Page:14926-14939
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Chen Xiu-Xiu¹,Xie Feng-Feng¹,Zhu Xiu-Jie¹,Lin Feng¹,Pan Shi-Shi¹,Gong Li-Hua¹,Qiu Jian-Ge²,Zhang Wen-Ji²,Jiang Qi-Wei²,Mei Xiao-Long²,Xue You-Qiu²,Qin Wu-Ming²,Shi Zhi²,Yan Xiao-Jian¹

Affiliation:

1. Department of Gynecology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China

2. Department of Cell Biology and Institute of Biomedicine, National Engineering Research Center of Genetic Medicine, Guangdong Provincial Key Laboratory of Bioengineering Medicine, College of Life Science and Technology, Jinan University, Guangzhou, Guangdong, China

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Homologous recombination proficient subtypes of high-grade serous ovarian cancer: treatment options for a poor prognosis group;Frontiers in Oncology;2024-06-04

2. The signalling axis CDK12-BRCA1 mediates dinaciclib associated radiosensitivity through p53-mediated cellular senescence;2024-04-28

3. The multi-CDK inhibitor dinaciclib reverses bromo- and extra-terminal domain (BET) inhibitor resistance in acute myeloid leukemia via inhibition of Wnt/β-catenin signaling;Experimental Hematology & Oncology;2024-03-04

4. The CDK Inhibitor Dinaciclib Improves Cisplatin Response in Nonseminomatous Testicular Cancer: A Preclinical Study;Cells;2024-02-20

5. Marine-Derived Compounds for CDK5 Inhibition in Cancer: Integrating Multi-Stage Virtual Screening, MM/GBSA Analysis and Molecular Dynamics Investigations;Metabolites;2023-10-18